利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.01 秒)

    COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
    2.
    发明申请
    COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY 审中-公开
    癌症免疫组织和方法

    公开(公告)号：WO2016118654A1

    公开(公告)日：2016-07-28

    申请号：PCT/US2016/014171

    申请日：2016-01-20

    申请人： IMMUNEXCITE, INC.

    发明人： RUBIN-BEJERANO, Ifat

    IPC分类号： A61K47/48 ,  A61K39/39 ,  A61K39/395

    CPC分类号： C07K16/28 ,  A61K39/395 ,  A61K47/61 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2818

    摘要： The present invention includes, among other things, β-1,6-glucan linked to an antibody directed to a cell present in a tumor microenvironment. T regulatory cells can be one type of cell present in the tumor microenvironment. In particular embodiments, the antibody is directed to a surface feature of a T regulatory cell, MDSC, or other immune cell. In certain embodiments, the antibody is directed to T regulatory cells, MDSCs, or other immune cells present in a tumor microenvironment. Compositions including β-1,6-glucan linked to an antibody directed to a T regulatory cell, MDSC, or other immune cell may be useful, e.g., in the treatment of a tumor or cancer in a subject in need thereof. Accordingly, the present invention provides, among other things, methods and compositions for treatment of a tumor or cancer.

    摘要翻译： 本发明尤其包括与针对存在于肿瘤微环境中的细胞的抗体连接的β-1,6-葡聚糖。 T调节细胞可以是存在于肿瘤微环境中的一种细胞。 在具体实施方案中，抗体针对T调节细胞，MDSC或其他免疫细胞的表面特征。 在某些实施方案中，抗体针对存在于肿瘤微环境中的T调节细胞，MDSC或其他免疫细胞。 包括与针对T调节细胞，MDSC或其他免疫细胞的抗体连接的β-1,6-葡聚糖的组合物可用于例如在有需要的受试者中治疗肿瘤或癌症。 因此，本发明尤其提供了用于治疗肿瘤或癌症的方法和组合物。

    IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF
    3.
    发明申请
    IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2009134891A3

    公开(公告)日：2009-11-05

    申请号：PCT/US2009/042117

    申请日：2009-04-29

    申请人： IMMUNEXCITE, INC. ,  RUBIN-BEJERANO, Ifat ,  FINK, Gerald, R. ,  KOHANE, Daniel, S.

    发明人： RUBIN-BEJERANO, Ifat ,  FINK, Gerald, R. ,  KOHANE, Daniel, S.

    IPC分类号： G01N33/53 ,  G01N33/563 ,  C07K16/18

    摘要： The invention is directed to β 1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β 1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The β 1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated β 1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.